OptiNose, Inc. (OPTN) News

OptiNose, Inc. (OPTN)

Today's Latest Price: $4.25 USD

0.29 (-6.39%)

Updated Jul 8 4:00pm

Add OPTN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter OPTN News Items

OPTN News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest OPTN News From Around the Web

Below are the latest news stories about OptiNose Inc that investors may wish to consider to help them evaluate OPTN as an investment opportunity.

Here is What Hedge Funds Think About OptiNose, Inc. (OPTN)

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

Yahoo | July 5, 2020

Optinose to develop COVID-19 treatment

Optinose ([[OPTN]] +25.2%) initiates development of a new product candidate, OPN-019, which will combine the Company’s proprietary nasal Exhalation Delivery System ((EDS)) technology with an antiseptic that has been recently shown in vitro to kill the virus that causes COVID-19.The Company is focused on supporting the initial stages of development and intends...

Seeking Alpha | June 30, 2020

Optinose launches development of COVID-19 prophylactic treatment

Optinose ([[OPTN]] +25.2%) initiates development of a new product candidate, OPN-019, which will combine the Company’s proprietary nasal Exhalation Delivery System ((EDS)) technology with an antiseptic that has been recently shown in vitro to kill the virus that causes COVID-19.The product will be positioned as prophylactic treatment for asymptomatic patients or those...

Seeking Alpha | June 30, 2020

Is OptiNose the Next Big Coronavirus Stock?

No summary available.

24/7 Wall street | June 30, 2020

Optinose Announces Anti-COVID-19 Product Candidate

OPN-019 will combine the Company’s proprietary nasal Exhalation Delivery System (EDS) technology with an antiseptic that has been recently shown in vitro to kill the virus that causes COVID-19. Because components of the drug-device combination product candidate, including both the active drug and delivery device, are currently commercially available in the U.S., the Company expects to be able to rapidly progress to a meeting with FDA to discuss an IND and then onward to clinical trials.

Yahoo | June 30, 2020

Optinose to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 9:00 a.m. ET. Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists.

Yahoo | June 22, 2020

Optinose Named a 2020 Best Place to Work by Philadelphia Business Journal

Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal’s “Best Places to Work” for 2020 in the medium-sized company category for the third year in a row. “Public recognition of Optinose as a ‘Best Place to Work’ is an honor for all of us, and is only possible because of the collective commitment and contributions of our team,” added Ramy Mahmoud, MD, President and Chief Operating Officer of Optinose.

Yahoo | June 19, 2020

Optinose to Host its Annual Meeting of Stockholders in Virtual Format

OptiNose, Inc. (OPTN) today announced that due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations and orders from federal and state governmental authorities, its Annual Meeting of Stockholders (the 2020 Annual Meeting) will now be held by means of a virtual format only. Stockholders will not be able to attend the meeting in person. The virtual format of the 2020 Annual Meeting will provide stockholders with the same rights and opportunities to participate as they would have at an in-person meeting.

Yahoo | May 27, 2020

Optinose to Present at the 2020 Jefferies Virtual Healthcare Conference

YARDLEY, Penn., May 26, 2020 -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today.

Yahoo | May 26, 2020

Optinose to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

Optinose (OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020, at 10:20 a.m. ET. Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists.

Yahoo | May 14, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6836 seconds.